Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;39(1):101954.
doi: 10.1016/j.beem.2024.101954. Epub 2024 Sep 21.

Progress in surgical approaches and outcomes of patients with pheochromocytoma and paraganglioma

Affiliations
Review

Progress in surgical approaches and outcomes of patients with pheochromocytoma and paraganglioma

Lindsay R Friedman et al. Best Pract Res Clin Endocrinol Metab. 2025 Jan.

Abstract

Significant advances have been made in the past few decades in surgical management and outcomes of patients with pheochromocytoma and paraganglioma. Improvements in preoperative hypertensive control with the implementation of alpha- and beta-adrenergic blockade has resulted in better intra-operative blood pressure control and less incidence of hypertensive crises, which had been a large source of morbidity in the past. Emphasis on anesthesia and surgical team communication has also assisted in minimizing intraoperative hypertensive events at critical points of the operation. Shifting away from open resection, the now standard-of-care laparoscopic and minimally invasive adrenalectomy offers less pain, shorter hospitalizations, and quicker recoveries. Patient underlying germline mutations can guide the timing, approach, and extent of surgery. Postoperative outcomes have significantly improved with recent advancements in perioperative care in addition to regimented biochemical and radiographic surveillance. Here, we highlight the recent advancements in surgical approaches and outcomes for patients with pheochromocytoma and paraganglioma.

Keywords: paraganglioma; pheochromocytoma; postoperative surveillance; preoperative management; surgery; surgical outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement The authors report no potential conflict of interests, financial or otherwise, related to content relevant to this article.

Similar articles

Cited by

References

    1. Davison AS, Jones DM, Ruthven S, Helliwell T, et al., Clinical evaluation and treatment of phaeochromocytoma. Annals of Clinical Biochemistry, 2017. 55(1): p. 34–38. - PubMed
    1. Corssmit EPM, Snel M, Kapiteijin E, Malignant pheochromocytoma and paraganglioma: management options. Current Opinions in Oncology, 2020. 32(1): p. 20–26. - PubMed
    1. Lenders JWM, Kerstens MN, Amar L, Prejbisz A, et al., Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020. 38: p. 1443–1456. - PMC - PubMed
    1. Pacak K, New Biology of Pheochromocytoma and Paraganglioma. Endocr Pract, 2022. 28(12): p. 1253–1269. - PMC - PubMed
    1. Hartmut PH, Neumann MD, Young WF, Eng C, Pheochromocytoma and Paraganglioma. New England Journal of Medicine, 2019. 381(6): p. 552–565. - PubMed

LinkOut - more resources